ES2101037T3 - Hexapeptido. - Google Patents

Hexapeptido.

Info

Publication number
ES2101037T3
ES2101037T3 ES92306942T ES92306942T ES2101037T3 ES 2101037 T3 ES2101037 T3 ES 2101037T3 ES 92306942 T ES92306942 T ES 92306942T ES 92306942 T ES92306942 T ES 92306942T ES 2101037 T3 ES2101037 T3 ES 2101037T3
Authority
ES
Spain
Prior art keywords
agent
alkyl group
isoleucine
valine
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92306942T
Other languages
English (en)
Inventor
Sakae Amagaya
Tadami Fujiwara
Masaki Aburada
Michio Nagasawa
Tsutomu Oyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura and Co filed Critical Tsumura and Co
Application granted granted Critical
Publication of ES2101037T3 publication Critical patent/ES2101037T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

HEXAPEPTIDO REPRESENTADO POR LA FORMULA (II): A-B-PRO-C-D-E (II) DONDE A ES LA FORMA L YO GRUPO AMINO N-TERMINAL ESTA ALQUILATADO O ACILADO, B ES LA FORMA LRMA L TRIPTOFAN, O FENILANINA, D ES LA FORMA LSOLEUCINA O LEUCINA Y E ES LA FORMA L EUCINA O LEUCINA, UNO DE LOS ATOMOS DE HIDROGENO DEL GRUPO AMINO DE LA CUAL PUEDE SER SUBSTITUIDO POR UN GRUPO ALQUIL C1 A C4, Y EL GRUPO CARBOXILO C-TERMINAL DE LA CUAL PUEDE SER SUBSTITUIDO POR COOR*, -CH2OR, O -CONHR, DONDE R* ES UN GRUPO ALQUILO C1 A C4 Y R ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO C1 A C4. EL HEXAPEPTIDO Y SUS SALES FARMACEUTICAMENTE ACEPTABLES SON UTILES COMO AGENTES MEDICOS, POR EJEMPLO COMO AGENTE ANTI-EDEMATOSO, AGENTE ANTI-CHOQUE, AGENTE ANTI-TROMBO, AGENTE ANTIARTERIOSCLEROTICO, AGENTE ANTI-ALERGICO, AGENTE HIPOTENSOR, AGENTE CURADOS DE HERIDAS Y AGENTE ANTI-INFLAMATORIO.
ES92306942T 1991-07-30 1992-07-30 Hexapeptido. Expired - Lifetime ES2101037T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21141691 1991-07-30

Publications (1)

Publication Number Publication Date
ES2101037T3 true ES2101037T3 (es) 1997-07-01

Family

ID=16605597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92306942T Expired - Lifetime ES2101037T3 (es) 1991-07-30 1992-07-30 Hexapeptido.

Country Status (11)

Country Link
US (1) US5393740A (es)
EP (1) EP0526192B1 (es)
JP (1) JP2803477B2 (es)
KR (1) KR100251496B1 (es)
AT (1) ATE149518T1 (es)
AU (1) AU661003B2 (es)
CA (1) CA2074967A1 (es)
DE (1) DE69217763T2 (es)
DK (1) DK0526192T3 (es)
ES (1) ES2101037T3 (es)
GR (1) GR3023058T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007705A1 (en) * 1993-09-15 1995-03-23 The Regents Of The University Of California Method for inhibiting vascular leakage and anti-inflammatory compounds
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JPH0848634A (ja) * 1994-08-05 1996-02-20 Akio Okamoto 角膜治療剤
GB9425582D0 (en) * 1994-12-19 1995-02-15 Iaf Biochem Int Peptides having immunomodulatory activity
WO1999052539A1 (en) * 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
US7087575B2 (en) * 2002-07-18 2006-08-08 Mayo Foundation For Medical Education And Research Treating the effect of nicotine
EP1768951A4 (en) * 2004-06-17 2011-06-15 Musc Found For Res Dev NON-NATURAL AMINO ACIDS
WO2006085417A1 (ja) * 2005-02-10 2006-08-17 Nagase Chemtex Corporation 生活習慣病を予防する食品
WO2007100718A2 (en) * 2006-02-24 2007-09-07 Denise Barbut Neurotensin receptor agonists and opioid receptor agonists
WO2010085661A1 (en) * 2009-01-23 2010-07-29 Musc Foundation For Reasearch Development Modified peptides and their use
CA2883447A1 (en) * 2012-09-04 2014-03-13 Jonathan B. Rothbard Therapeutic compositions and related methods
CN105541642A (zh) * 2016-01-11 2016-05-04 罗梅 一种手性（s）-亮氨醇盐酸盐的合成方法
CZ309857B6 (cs) * 2022-03-31 2023-12-20 Contipro A.S. Hexapeptid, kompozice zahrnující tento hexapeptid a jejich topické použití

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) * 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
IT1190389B (it) * 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
JP2714425B2 (ja) * 1988-03-11 1998-02-16 エーザイ株式会社 ポリペプチド
FI890918A7 (fi) * 1988-03-11 1989-09-12 Eisai Co Ltd Polypeptider.

Also Published As

Publication number Publication date
EP0526192B1 (en) 1997-03-05
DE69217763T2 (de) 1997-07-10
KR100251496B1 (ko) 2000-05-01
EP0526192A3 (en) 1993-12-08
ATE149518T1 (de) 1997-03-15
AU661003B2 (en) 1995-07-13
JPH05194590A (ja) 1993-08-03
KR930002373A (ko) 1993-02-23
AU2065792A (en) 1993-02-04
DE69217763D1 (de) 1997-04-10
US5393740A (en) 1995-02-28
EP0526192A2 (en) 1993-02-03
GR3023058T3 (en) 1997-07-30
DK0526192T3 (da) 1997-07-28
JP2803477B2 (ja) 1998-09-24
CA2074967A1 (en) 1993-01-31

Similar Documents

Publication Publication Date Title
DK0526192T3 (da) hexapeptid
US4692459A (en) Anti-hypertensive agents
KR970015598A (ko) 환상 결합 억제제
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
IL129238A0 (en) N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds
TR200100438T2 (tr) Hepatit C inhibitörü peptitler
ES2164218T3 (es) Derivados de camptotecina.
ATE194597T1 (de) Substituierte salizylsäure zur behandlung von autoimmunkrankheiten
NO911787D0 (no) Peptidaminer samt fremgangsmaate for fremstilling derav.
SE9100342D0 (sv) Novel steroid esters
MY123908A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
GR3032220T3 (en) Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives for the treatment of diseases which are mediated by non-enzymatical glycosylation
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ATE14226T1 (de) Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
AR006523A1 (es) Compuestos ciclicos, inhibidores de la adhesion
ATE113606T1 (de) Peptide und diese peptide enthaltende wirkstoffe gegen dementia.
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
HU9301520D0 (en) Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents
DK0513613T3 (da) Hidtil ukendte polypeptider med affinitet for lipopolysaccharider og anvendelse heraf
ATE181333T1 (de) Azirdin-derivate, deren herstellung und verwendung
KR890701545A (ko) 건선치료를 위한 제약학적 조성물
CO5160245A1 (es) Compuestos organicos inhibidores de las proteinasas de cisteina, en particular inhibidores de catepsina k de arilaminoalquilamida, y su uso farmaceutico para el tratamiento o la profilaxis de enfermedades o condiciones medicas en donde este implicada
DE68917211D1 (de) N-(5,6,7,8-Tetrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)-glutaminsäure-Derivate.
ATE89264T1 (de) Arzneimittel enthaltend nitroxyalkylamine mit amidfunktion und verfahren zur herstellung dieser verbindungen.
NO894720D0 (no) Farmasoeytisk aktivt protein.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526192

Country of ref document: ES